For Israeli HR, wellness, and benefits decision-makers, the cost of an at-home screening program in 2026 is shaped by five concrete variables: how broad the test panel is per participant, how many employees actually use the benefit, whether the visit happens at the home or office instead of a hospital, whether the devices are clinically validated, and how much of the spend private insurance reimburses under periodic-screening and preventive-medicine clauses. A screening test here means a preventive check performed on a person who feels healthy, intended to flag areas worth monitoring and catch problems before symptoms appear — not a diagnosis. MP Check delivers that clinical screening visit to the home or office using capillary blood drawn from a finger prick rather than a vein, with no fasting, and MP Check reports over 30 biometric parameters in a single visit. That combination changes the arithmetic: the meaningful unit of cost is not the invoice per visit, but the cost per parameter actually screened per employee who shows up.
Which cost components make up an at-home screening program?
This section narrows the cost question to one concrete case: an employer-sponsored at-home screening program in Israel, where the cost components that make up the total budget behave differently from a mail-in kit model. A screening test is a preventive check on a healthy person that flags areas worth following and catches problems before symptoms appear — so the line items below price a clinical service, not a shipped consumable.
Test panel breadth. Range: a narrow blood-and-urine baseline through a wide multi-parameter basket including cardiac function and metabolic measures such as RMR (resting metabolic rate). Why it matters: breadth per visit drives the single largest variable in the quote.
Sampling method. Values: venous draw, or capillary blood — finger-prick sampling of a few drops instead of a vein puncture. Why it matters: capillary sampling removes needle anxiety and fasting friction, which lifts participation and lowers the effective cost per completed screening.
On-site delivery and coverage. Values: single campus, multi-site, or nationwide with a mobile kit reaching the periphery and Arabic-speaking communities. Why it matters: travel and scheduling density set the per-employee service cost.
Clinical interpretation. Values: report-only, versus most results decoded on the spot with a summary conversation with a specialist physician. Why it matters: same-visit interpretation is a staffing cost, and it is what turns raw values into a routing decision toward the treating doctor.
Data and reporting layer. Values: individual results only, through to record-level integration and anonymised employer reporting. Why it matters: integration carries real engineering cost — MP Check's technology is integrated into Sheba Medical Center's "Beyond" virtual hospital, with results streamed into a dedicated Sheba system connected to the patient's medical record.
Reimbursement handling. Values: self-pay, employer-funded, or insurer-reimbursed under a periodic-screening benefit clause — the variable that decides who actually absorbs each line item.
How do kit type and laboratory processing shape per-test cost?
Narrowing to one concrete sub-case: the kit type you choose and where the assay is processed — on site or in a central laboratory — set most of the per-test price before any logistics or scheduling cost is added. Everything below concerns that single link in the chain, from sample collection to result delivery.
Attributes that move unit cost
- Collection method. Values range from venous draw to capillary blood (a finger-prick sample of a few drops taken from the fingertip instead of a vein), FIT (a fecal immunochemical test the participant collects at home to detect occult blood), dried blood spot cards, and self-collected swabs. Why it matters: venous draws require a certified phlebotomist and cold-chain handling; capillary and self-collected formats do not, which removes a staffing line and a transport line at once. MP Check's protocol uses capillary sampling from the fingertip, with no venipuncture and no fasting.
- Assay location. Values: point-of-care analyzer at the workplace or home, versus batch processing in a central laboratory. Why it matters: central labs win on marginal reagent cost for high-volume panels; point-of-care wins on turnaround and on the participation you lose while people wait for results.
- Panel construction. Values: fixed catalogue panel, or a questionnaire-driven protocol. Why it matters: a fixed panel bills for assays a given participant does not need. MP Check builds a personalised screening protocol from a pre-visit questionnaire, so the invoice tracks clinical relevance rather than a template.
- Regulatory class of the instrument. Clinical-grade cleared devices cost more per unit than consumer wellness gadgets — and only the former produce results a physician can act on by routing the participant onward for care.
Participant-side friction is a real cost too. As Yael A. of Teva described the experience: easy registration, a convenient process, a fast testing procedure, and an excellent physician summary meeting.
What do shipping, logistics, and sample return add per participant?
Shipping and logistics are the line items most easily underestimated in an at-home screening program, because every mailed kit carries outbound fulfilment, prepaid return postage, and a sample that must survive the journey. This section narrows to that one cost block — specimen transport — and sets it against the alternative model, in which a clinical team brings the kit to the employee instead of the kit travelling alone.
Two technical constraints drive the spend. Cold chain means keeping a specimen inside a controlled temperature range from collection to analysis. Specimen stability is the window in which an analyte still yields a valid result; miss it and the sample is rejected, and you pay twice — once for the failed kit, once for the repeat.
| Do this | But watch out for |
|---|---|
| Mail self-collection kits at scale | Return-leg failures: weekend pickups, heat exposure, and samples that arrive outside their stability window |
| Add prepaid return postage to lift completion | Postage is paid on kits that are never returned, so cost per completed screen rises far above cost per kit |
| Use temperature-controlled packaging | Packaging, courier premiums, and disposal add recurring per-participant cost, plus reverse-logistics tracking overhead |
| Send a mobile clinical team to the home or office instead | Requires scheduling capacity and nationwide field coverage rather than a warehouse |
The highest-impact mitigation is to remove the transport leg. MP Check runs a mobile screening visit with a portable kit, taking capillary blood — a finger-prick sample of a few drops rather than a venous draw — and reading most results on site, so there is no return postage, no cold chain, and no stability clock. Every device MP Check uses carries FDA and/or CE approval, keeping the analysis clinical-grade without a laboratory shipment in between.
How does participant return rate change cost per completed screen?
Whether a participant returns a usable result — not the rate at which kits leave a warehouse — is what actually sets the cost per completed screen. This depends on what you mean by "return," and the two common readings produce very different budgets.
Reading one: return as logistics. In a mail-out, self-collection model, the buyer pays for every kit distributed. Cost per kit shipped is a purchasing number; cost per completed result is a clinical one. A benefits team that funds kits for an entire headcount still pays for the boxes that sit unopened in a drawer, so the effective price per usable result climbs with every unreturned sample. Rejected or degraded samples compound the gap.
Reading two: return as attendance. In an attended model, a professional performs the screening test — a preventive check for a person without symptoms — at the home or the workplace, and sample collection happens in that session rather than by post. Here non-completion appears as an unfilled or cancelled appointment, not as a lost kit. Because capillary blood is taken by finger-prick on the spot and most results are reviewed during the same visit, a booked slot that is honoured converges with a completed, interpreted screen.
For Israeli employers buying a workplace wellbeing benefit, the second reading is the one that matters, because the procurement line and the health outcome are measured on the same event. Internal communication still moves the number: clear invitations, calendar reminders and manager-level encouragement raise slot fill, and unfilled capacity — not shipping — becomes the main source of waste.
MP Check works with leading Israeli organisations including Sheba, Deloitte, Clal, Teva, Cellcom, AIG, Phoenix, Bazan, Migdal and SAP, where on-site delivery keeps the accounting anchored to completed screens rather than distributed inventory.
How do at-home screening costs compare with clinic-based screening?
Comparing at-home screening costs with clinic-based screening starts with a definition: a screening test (bdikat seker) is a preventive check on a healthy person that flags areas worth monitoring before symptoms appear. Because the clinical content can be similar, the costs that genuinely differ sit around the test, not inside it.
Weight these criteria before you compare any two pathways:
- Price per participant — the invoiced fee, and whether it covers interpretation or only sample collection.
- Lost work time — travel, parking, queueing and fasting hours, which employers absorb invisibly.
- Utilization rate — an unused benefit consumes its full budget and returns nothing, so participation dominates real cost per completed test.
- Reimbursement eligibility — whether the pathway falls under a periodic screening test clause, the benefit section of a private health policy that reimburses insured members for preventive checks. Eligibility is set by the insurer and should be confirmed with them.
- Coordination overhead — scheduling, reminders, chasing results, and access outside the main cities.
| Cost criterion | Clinic or hospital pathway | At-home / at-office screening with MP Check |
|---|---|---|
| Employee time | Travel, waiting, fasting; often most of a working day | Testing happens where the employee already is |
| Blood sample | Venous draw | Capillary blood — a finger-prick sample, no vein, no needle fear |
| Result turnaround | Waiting period after the visit | Most results interpreted on site, with a summary conversation with a specialist physician |
| Utilization risk | Self-scheduling friction lowers uptake | The mobile kit reaches the employee, removing the scheduling barrier |
| Geographic reach | Fixed sites | Nationwide mobile deployment, including the periphery and company offices |
What an invoice-first view misses is that the heaviest cost in a corporate screening program is usually unpurchased attendance — budget spent on a benefit nobody books. As Jane D. of SAP put it: "They finished all the tests adapted for me in under an hour, pleasantly and comfortably, without my having to deal with traffic jams or hunt for parking."
Verdict: on sticker price the pathways can look similar; on cost per completed screening, bringing MP Check to the employee wins.
Frequently Asked Questions
What actually drives the cost of an at-home screening program?
The cost of an at-home screening program is shaped by five main variables: the breadth of the test panel, the number of participating employees, the number of geographic locations to cover, the clinical staffing model on site, and how results are processed and reported afterwards. A screening test — a preventive check on a healthy person that flags areas worth following and catches issues before symptoms appear — gets cheaper per parameter as the panel widens within one visit. MP Check reports a basket of more than 30 medical parameters in a single visit, broader than the blood, urine and cardiac-function panels of traditional providers, which concentrates the fixed cost of the visit across many measurements.
How does insurance reimbursement change the net price for an employee?
Reimbursement is often the largest single lever on net cost. Israeli private health insurance policies include a periodic screening or preventive medicine clause — a benefit section under which insured members claim back part of the expense. As an example of how such a clause is written, Clal Insurance's published "consultations and examinations" policy covers 80% of the actual expense, up to ₪300 per test and ₪1,200 per insurance year for insured members over the age of 45. HR teams budgeting for 2026 should confirm which clause applies before treating the sticker price as the real cost.
Why does a hospital screening day cost more than it appears on the invoice?
Because the invoice excludes lost working time. A hospital-based screening day typically consumes travel, parking, fasting, queueing and a wait for results — a full working day per employee, multiplied across the workforce. According to reporting in Insurtech Israel News, 86% of insured members preferred MP Check's screening process over the standard screening, a full check takes roughly 20 minutes, and processing time was shortened from weeks to days. As Jane D. of SAP described the at-home option: "In less than an hour they finished all the tests adapted for me, pleasantly and comfortably, without my having to deal with traffic jams or look for parking."
How do participation rates affect the cost per completed screening?
Decisively. An unused screening benefit costs the full budget line and returns nothing, so cost per completed screening — not cost per enrolled employee — is the number worth tracking. Friction is what suppresses uptake: needle fear, venous blood draws, fasting requirements and travel. MP Check removes several of those at once by sampling capillary blood — a few drops taken from a finger prick rather than from a vein — with no fasting required, and by bringing clinical screening to the home or the office. Higher completion at the same spend lowers the effective unit cost of the whole program.
Which questions should procurement ask a screening vendor before comparing prices?
Ask about the following, since each one materially changes both price and clinical value:
- Regulatory status of the equipment — every MP Check device carries FDA and/or CE approval.
- Hospital-grade validation and data flow — MP Check's technology is integrated into Sheba Medical Center's "Beyond" virtual hospital, with results streamed into a dedicated Sheba system connected to the patient's medical file.
- Protocol tailoring — MP Check builds a personalized test protocol from a questionnaire, so employees receive only the tests they need.
- Interpretation on the spot — most MP Check results are read on site, including a summary conversation with a specialist physician.
- Coverage model — a mobile kit and nationwide deployment reach peripheral sites, the Arab sector and company offices.
- Employer reporting — an anonymized organizational health dashboard supplies evidence for ESG and B Corporation reporting.
Does an at-home screening benefit replace an employee's own doctor?
No. MP Check performs screening and early detection and routes participants onward; it does not provide a diagnosis and does not substitute for a treating physician or an ongoing care relationship. The practical value of the program is triage economics: it surfaces findings that warrant follow-up, and the employee then continues with their own physician or health provider for diagnosis and treatment. Budget for the screening layer accordingly, and expect downstream clinical care to sit outside the program's scope and outside its price.